Drug intelligence / Profile preview

ZM015

Development stage: Discontinued
Lead developer: Zumutor Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZM015 is a preclinical-stage monoclonal antibody being developed by Zumutor Biologics, in collaboration with Brigham and Women's Hospital, for the treatment and prevention of COVID-19 (SARS-CoV-2 infection). Discovered using Zumutor's proprietary INABLR® human antibody platform, ZM015 is designed to target the SARS-CoV-2 spike glycoprotein, neutralizing the virus by disrupting its entry and fusion into host cells. The program received funding from the United States-India Science & Technology Endowment Fund (USISTEF) in 2020, but development has since been discontinued.

Targets

SARS-CoV-2 spikeFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)C1Q (Complement C1q)FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on ZM015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZM015.

Explore the full profile